Figure 2.

Modeled Prevalence of Prescribed Analgesic Use in Relation to Bariatric Surgery, by Surgical Procedure^a

A. Among participants who underwent RYGB, the prevalence of any prescription analgesic use, and specifically non-opioid analgesic use, increased over time (P for both <.001), first decreasing from baseline to 6 months (P for both<.001) and then increasing such that year-7 prevalence was higher than baseline (P for both<0.05). The prevalence of NSAID use followed a quadratic trend (P<.001), decreasing from baseline to 6 months (P<.001) before increasing over time. However, post-surgery prevalence remained lower than baseline through year-7 (P=0.01). B. Among participants who underwent LAGB, the prevalence of any prescription analgesic use increased over time (P=0.01), but was not significantly different from baseline at 6 months (P=0.45) or year-7 (P=0.50). The prevalence of non-opioid analgesic use did not differ over time (p=0.34) or differ from baseline at 6-month (P=0.50) or 7-year (P=0.83). The prevalence of NSAID use followed a quadratic trend over time (P=0.01) but was not significantly different from baseline at 6 months (P=0.23) or year-7 (P=0.99).

Abbreviations: Laparoscopic adjustable gastric banding (LAGB); non-steroidal anti-inflammatory drugs (NSAID); Roux-en-Y gastric bypass (RYGB).

^aModels were adjusted for baseline factors related to missing follow-up data (i.e., site, age, smoking status). Observed and modeled data for these and “other” procedures is reported in eTables 5 and 6 [Supplement], respectively. ^bData are based on observations until January 31, 2015; data collection ended before 429 RYGB and 173 LAGB participants were eligible for a 7 year assessment.